MktsMarkets

Tenax Therapeutics, Inc.
NASDAQ: TENXKey statistics
TENX News
Stories mentioning TENX from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | 0.00 | ||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Operating Expenses | ||||||||
| Research & Development | 11,539 | 10,540 | 10,328 | 6,121 | 5,683 | 4,594 | 3,112 | 2,327 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 16,573 | 16,449 | 16,806 | 11,792 | 11,338 | 7,295 | 4,619 | 3,671 |
| Operating Income (Loss) | (16,573) | (16,449) | (16,806) | (11,792) | (11,338) | (7,295) | (4,619) | (3,671) |
| Interest Income | ||||||||
| Interest Expense | (1.00) | 7.00 | 9.00 | |||||
| Other Expense | (4.00) | (9.00) | (15.00) | (9.00) | 0.00 | 117.00 | 0.00 | 1.00 |
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (15,716) | (15,540) | (15,804) | (10,847) | (10,408) | (6,267) | (3,961) | (3,575) |
| Earnings Per Share (Basic) | (0.35) | (0.40) | (0.40) | (0.27) | (0.28) | (0.41) | (0.19) | (1.83) |
| Earnings Per Share (Diluted) | (0.35) | (0.40) | (0.40) | (0.27) | (0.28) | (0.41) | (0.19) | (1.83) |
| Weighted Average Shares Outstanding (Basic) | 45,226 | 39,217 | 39,741 | 39,572 | 36,585 | 15,272 | 21,161 | 1,958 |
| Weighted Average Shares Outstanding (Diluted) | 45,226 | 39,217 | 39,741 | 39,572 | 36,585 | 15,272 | 21,161 | 1,958 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About TENX
Tenax Therapeutics, Inc. (NASDAQ: TENX) is a stock listed on the Nasdaq Stock Market under the ticker symbol TENX. It last traded at $1.81 (Nov 4, 2026, 4:00 PM ET), down 1.6% on the day. That gives Tenax Therapeutics a market capitalisation of $68.9M.
Over the past 52 weeks TENX has traded between $1.31 and $19.40.
Revenue for the quarter ended Mar 31, 2026 was $0; a net loss of $15.7M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | $0 | -$15.7M |
| Dec 31, 2025 | — | -$15.5M |
| Sep 30, 2025 | — | -$15.8M |
| Jun 30, 2025 | — | -$10.8M |
From Tenax Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…